KindlyMD (NASDAQ:NAKA) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of KindlyMD (NASDAQ:NAKA) to a sell rating in a report released on Saturday morning.

A number of other analysts have also commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research note on Wednesday, October 8th. B. Riley began coverage on KindlyMD in a research note on Wednesday. They issued a “buy” rating and a $2.00 price target on the stock. Finally, Maxim Group began coverage on KindlyMD in a research note on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.00.

KindlyMD Trading Down 4.9%

NAKA opened at $0.72 on Friday. The firm has a market capitalization of $297.79 million, a price-to-earnings ratio of -0.84 and a beta of 31.10. KindlyMD has a 52 week low of $0.65 and a 52 week high of $34.77. The firm’s fifty day moving average is $4.58.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.34) EPS for the quarter. The company had revenue of $0.41 million for the quarter. KindlyMD had a negative net margin of 244.00% and a negative return on equity of 131.09%.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.